tirzepatide method of action Mechanism (MOA) of Tirzepatide, a New Era of

Highlights The first incretin hormone, gastric inhibitory peptide, was identified in the early 1970s, followed by the discovery of glucagonlike peptide 1 (GLP-1) in the 1980s [1]

Increases in calcitonin levels have been observed in some patients, though the clinical significance remains uncertain

The key will be balancing accessibility with appropriate medical oversight to ensure these powerful medications are used safely and effectively

Lunch: Salmon (Red/sockeye), filets with skin

The most common adverse effects are gastrointestinal in nature , including nausea (reported in 20-30% of patients), diarrhea, vomiting, constipation, and abdominal discomfort